Trial reportLeukemia & lymphoma2023
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.
Open access · greenAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Leukemia & lymphoma, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
1.8field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review and meta-analysis.Blood advances · 2026Pooled it
- American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.Blood advances · 2026Guideline
- Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta-Analysis of Observational Studies and Randomized Controlled Trials.Journal of the American Heart Association · 2024Pooled it
- A retrospective analysis of upfront treatment strategies in chronic myelomonocytic leukemia: impact on survival and response patterns.Haematologica · 2026Article
- Hijacking the helpers: platelet and neutrophil trafficking in AML and therapeutic exploitation.Experimental hematology & oncology · 2026Review
- Review
- One step further in targeting acute leukemia by combining antibody-based immunotherapies and small molecule inhibitors.Cancer cell international · 2025Review
- Comparative Analysis of the TCR Repertoire in Bone Marrow CD8European journal of immunology · 2025Article
- Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances.Cancers · 2025Review
- Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape.Current oncology (Toronto, Ont.) · 2024Review
- Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies.Therapeutic advances in medical oncology · 2024Article
- Checkpoint inhibition in hematologic malignancies.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 12 institutions in 3 countries.
Sarit AssoulineMcGill University - Jewish General Hospital, Montreal, Canada.
Laura C MichaelisMedical College of Wisconsin, Milwaukee, WI, USA.
Megan OthusSWOG Statistics and Data Management Center, Seattle, WA, USA.
Annette E HayQueen's University, Kingston, Canada.
Roland B WalterFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Meagan A JacobyWashington University School of Medicine, St. Louis, MO, USA.
Mark A SchroederWashington University School of Medicine, St. Louis, MO, USA.
Geoffrey L UyWashington University School of Medicine, St. Louis, MO, USA.
Lisa Y LawKaiser Permanente NCAL, Roseville, CA, USA.ORCID 0000-0001-7343-8212
Faisal CheemaKaiser Permanente, Santa Clara, CA, USA.
Kendra L SweetMoffitt Cancer Center, Tampa, FL, USA.
Adam S AschUniversity of Oklahoma HSC, Oklahoma City, OK, USA.
Jijun Jane LiuIllinois CancerCare/Heartland NCORP, Peoria, IL, USA.
Anna B MoseleyMedical College of Wisconsin, Milwaukee, WI, USA.ORCID 0000-0002-7514-7360
Tracy MaherSWOG Data Operations Center/Cancer Research and Biostatistics, Seattle, WA, USA.
Laura L KingsburySWOG Data Operations Center/Cancer Research and Biostatistics, Seattle, WA, USA.
Min FangFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jerald RadichFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Richard F LittleCancer Therapy and Evaluation Program (CTEP), National Cancer Institute, Bethesda, MD, USA.
Harry P ErbaDuke University Medical Center, Duke Cancer Institute, Durham, NC, USA.
Fred Hutch Cancer Center · USWashington University in St. Louis · USCancer Research And Biostatistics · USKaiser Permanente · USMedical College of Wisconsin · USDuke Medical Center · USHeartland Cancer Research · USJewish General Hospital · CAMoffitt Cancer Center · USNational Cancer Institute · MYOklahoma City University · USQueen's University · CA
Funding
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MSWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Michael L. LeBlanc · 2014 to 2026
$115.2MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5MKaiser Permanente NCI National Community Oncology Research Program, NCORPUG1CA189821 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI Jennifer Marie Suga · 2014 to 2026
$44.4MHeartland Cancer Research NCORPUG1CA189830 · NCI · DECATUR MEMORIAL HOSPITAL · PI Bryan A. Faller · 2014 to 2026
$40.9MNCIC Clinical Trials Group - Canadian Collaborating Clinical Trials NetworkU10CA180863 · NCI · QUEEN'S UNIVERSITY AT KINGSTON · PI Janet Ellen Dancey · 2014 to 2026
$40.4MA Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical TrialsUG1CA233193 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Muhammad Furqan · 2019 to 2026
$13.7MWASHINGTON UNIVERSITY / SITEMAN CANCER CENTER LEAD ACADEMIC SITEUG1CA233339 · NCI · WASHINGTON UNIVERSITY · PI NANCY L BARTLETT, Clifford Grant Robinson · 2019 to 2026
$11.3MMedical College of Wisconsin Lead Academic Participating Site RenewalUG1CA233198 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI William H Bradley, Elizabeth M Gore · 2019 to 2026
$5.0MHutchinson Center as Lead Academic Participating Site (UG1)UG1CA233328 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Evan Yu · 2019 to 2026
$4.3MIntegrated Translational Genoproteomics Center at Washington UniversityU10CA180860 · NCI · WASHINGTON UNIVERSITY · PI CHUNG, CHRISTINE H, ELLIS, MATTHEW J · 2014 to 2018
$2.6MNCI NIH HHS P30 CA076292NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180860NCI NIH HHS U10 CA180863NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA189821NCI NIH HHS UG1 CA189830NCI NIH HHS UG1 CA233193NCI NIH HHS UG1 CA233198NCI NIH HHS UG1 CA233328NCI NIH HHS UG1 CA233339
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Myeloid, AcuteLeukemia, Myelomonocytic, ChronicMyelodysplastic SyndromesAzacitidineHumansMiddle AgedNivolumabAzacitidineNivolumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.